

Children with seizures and radiological diagnosis of focal cortical dysplasia: can drug resistant epilepsy be predicted earlier?

Ido Ben Zvi¹, Noelle Enright², Felice D'arco³, M Zubair Tahir^{1,4}, Aswin Chari^{1,4}, J Helen Cross^{2,4}, Christin Eltze^{2,4}, Martin M Tisdall^{1,4}.

1. Paediatric Neurosurgery Department. Great Ormond Street Hospital, UK
2. Paediatric Neurology Department. Great Ormond Street Hospital, UK
3. Paediatric Radiology Department. Great Ormond Street Hospital, UK
4. UCL Great Ormond Street Institute of Child Health, UK

Corresponding author: Ido Ben Zvi, Great Ormond Street, London, UK. WC1N3JH, 0044-730-6000321, idobenz@gmail.com

Key words: Focal cortical dysplasia, drug-resistant epilepsy, epilepsy surgery

Number of text pages-23

Number of words-3407

Number of references-33

Number of figures-3

Number of tables-4

Supplementary material-1

ORCID number:

Ido Ben Zvi-0000-0003-3700-0672

Martin Tisdall-0000-0001-8880-8386

Abstract

Objective. Focal cortical dysplasia (FCD) is a malformation of cortical development and is associated with drug-resistant epilepsy. Standard indication for epilepsy surgery is drug resistance (as defined by the ILAE). Given the high incidence of drug-resistance in these children, this delay may not be warranted. The aim of the study was to determine the proportion of patients with a presumed FCD who develop drug resistance and evaluate post-operative outcomes.

Methods. This study incorporated a survey within a regional paediatric epilepsy network and a retrospective database review of a paediatric epilepsy centre serving the network to identify children with epilepsy and a presumed FCD on MRI.

Results. The survey revealed that 86% of the patients with epilepsy and presumed FCD on MRI within the network were referred to our centre. Of 139 paediatric patients included in the study, 131 (94.2%) had drug-resistant epilepsy. 110 (83.9%) patients were referred to epilepsy surgery, of whom 97 underwent surgery. Of 92 with 1-year postoperative follow-up, 59.8% had an Engel class 1 (seizure free) outcome. Concordance of location between MRI and ictal EEG was strongly associated with Engel class 1 outcome ($p < 0.001$), as was older age at seizure onset ($p = 0.03$). Time from diagnosis to surgery, number of medications, type of surgery and histology were not associated with improved outcome.

Significance. Our data suggest that most children presenting with seizures and a radiological diagnosis of FCD will develop drug-resistant epilepsy and are candidates for epilepsy surgery. The main outcome predictors are the correlation between MRI and ictal EEG localization and age at onset. This suggests that patients with FCD and epilepsy may be considered for surgery before traditional criteria of drug resistance are met. This change in practice has the potential to improve quality of life and cognitive function, and reduce burden on epilepsy services.

Key words: Drug-resistant epilepsy, epilepsy surgery, focal cortical dysplasia

Introduction

Focal cortical dysplasia (FCD) is a localized malformation of cerebral cortical development believed to form between weeks 10 and 20 of human embryonic development.¹⁻¹² FCDs are classified according to the ILAE task force consensus, based on histopathology and associated additional pathology.¹ Numerous publications have noted an association between FCDs and drug-resistant focal epilepsy, with it being the most common pathology responsible for focal onset epilepsy coming to surgical resection in children.¹³⁻¹⁷

The standard indication for epilepsy surgery in patients with focal onset seizures as a result of FCD is drug-resistance. This is defined by the International League Against Epilepsy (ILAE) as failure of two adequately tolerated and appropriately dosed anti-epileptic agents to achieve seizure control.¹⁸ These data, however, are based on epilepsy as a result of all etiologies and is not specific to either focal cortical dysplasia or epilepsy caused by parenchymal brain lesions. In the context of surgically treated FCDs, less than 10% of the patients will respond to a third antiepileptic medication as opposed to 50-75% of patients that will become seizure free after surgery.^{12,19-22} However, it may be possible to predict drug-resistance at an earlier stage thus allowing earlier epilepsy surgery and potentially improving long term outcomes. There have been several studies, including from our own institution, examining disease course and outcomes following epilepsy surgery in the context of low-grade brain tumours.²³⁻²⁵ These have shown that the majority of cases do not respond to medical treatment alone and will eventually go on to require epilepsy surgery.

Seizure freedom is not the only aim of epilepsy surgery in many patients. There is evidence to suggest treating seizures in a timely manner improves not only seizure outcome but also long-term cognitive functioning,^{20,23,26-29} possibly related to the deleterious effect of long-term anti-epileptic medication.³⁰ Another possibility is the negative correlation demonstrated between both the amount of seizures prior to an operation and the length of time from the first seizure

to an operation to seizure outcome and cognitive ability.^{20,23,26-29} This raises the possibility that early identification of surgical candidacy may result in better long-term outcomes. Thus, if the risk of drug-resistance and hence indication for surgical management, in a particular cohort, is high, then postponing surgical intervention to complete the two-drug-resistance paradigm may not be optimal and the delay may produce a poorer outcome. In order to determine if early epilepsy surgery treatment of FCD might be warranted we set out to ascertain the natural history of children presenting with seizures and presumed FCD.

Our study aimed to determine the proportion of patients with seizures and presumed FCDs on MRI who go on to develop drug-resistance and become surgical candidates. We also investigated factors associated with drug resistance and predictors for seizure free outcome after epilepsy surgery. In order to be able to generalize the applicability of our findings, we also assessed our referral patterns from secondary providers. Our hypothesis was that the vast majority of patients with epilepsy and a radiological diagnosis of FCD would develop drug resistance and become surgical candidates, raising the possibility of considering surgical resection at an earlier stage than current treatment paradigms.

Methods

Study Design

This two-part study involved a survey of clinicians in the north London paediatric epilepsy referral network and a single centre retrospective cohort study. These two parts were undertaken simultaneously.

Cohort Study

A single centre retrospective case series of children with presumed FCD on MRI, who had been reviewed in the epilepsy service at Great Ormond Street Hospital (GOSH) for Children between 2012 and 2019 was performed.

Inclusion and Exclusion Criteria

The electroencephalogram (EEG) and the magnetic resonance imaging (MRI) report databases at GOSH were interrogated for the terms ‘dysplasia’ between 2012 and 2019 in order to identify all children with FCD who attended the hospital. All MRIs were formally reviewed by an experienced tertiary centre paediatric neuroradiology consultant with a special interest in paediatric epilepsy. Patients were eligible for inclusion if they were under 18 years of age at the time of diagnosis, with MRI findings suggestive of focal cortical dysplasia (blurring of the grey white matter junction, smooth cortical thickening, subcortical abnormal signal and/or transmantle sign), and epilepsy. Patients were excluded if the pre-surgical brain MRI findings were unclear, or if the imaging revealed FCD not in isolation, e.g.: in the context of tuberous sclerosis or hemimegalencephaly. Seizure freedom was defined as a minimum of 12 months from the last seizure to the date of the last documented review of the patient.

Data Collection

Demographics, clinical assessment, imaging, neurophysiology, and surgical procedure data were collected retrospectively. Scalp video EEG reports performed as part of pre-surgical evaluation were reviewed. Interictal and ictal epileptiform discharges were recorded and classified as concordant if the interictal discharges and ictal onset arose from the same lobe (or brain region in cases of multilobar involvement). Interictal and ictal epileptiform discharges were categorised according to their location in relation to the anatomical region of the FCD on MR imaging. EEG data and MRI were considered as concordant if the EEG report stated that interictal discharges, or ictal onset was arising from the same lobe or quadrant (in case where the EEG findings arose from more than one lobe e.g occipito-parietal) as the MRI lesion, or the report specifically stated they were in keeping with the known lesion. The surgical decision making was at the discretion of the epilepsy surgery multidisciplinary team (MDT). In the context of a presumed epileptogenic lesion on MRI, a lack of complete concordance between

MRI and EEG was discussed on a case-by-case basis. Patients with significantly discordant findings were considered for intracranial EEG evaluation.

Seizure outcome postoperatively was calculated using the Engel scale³¹ at 12-month follow-up. Information regarding any adverse events was obtained from a prospectively maintained neurosurgical operative database.

Post-operative EEGs were reviewed for presence of epileptiform discharges and post-operative MRI scans were reviewed for residual lesion by a neuroradiologist. Drug reduction typically commences 6 months postoperatively, with 2-3 months of tapering for each drug. This is evaluated for every patient individually and remains under clinicians' decision.

Survey

Great Ormond Street Hospital for Children provides specialist paediatric epilepsy services together with 3 other neurology centres in North London. Out of four paediatric epilepsy surgery centres in England, GOSH neurosurgery is the largest, receiving some of the most challenging patients. To address bias that might arise from the group of patients being presented to GOSH as being those with drug-resistant epilepsy (DRE), and not representing the general population of patients with FCD, we conducted an on line survey, addressing paediatricians and paediatric neurologists of the North Thames Paediatric epilepsy network (NTPN), a network in our geographical referral area consisting of hospital and community clinic based paediatric services, as well as 3 other paediatric neurology centres. The survey was sent to the whole referral network comprising a total of 52 consultant paediatricians or paediatric neurologists primarily involved in the care of patients with epilepsy.

Clinicians were asked using an online questionnaire as to whether they referred all patients with epilepsy, and presumed FCD on MRI, to our specialist epilepsy service/epilepsy surgery programme for evaluation, or confined their referrals to those with drug-resistant epilepsy

alone (see the online questionnaire-Appendix S1 in supplementary material). The survey was undertaken anonymously in order to protect confidentiality.

Statistical Analysis

Differences between groups were assessed using one-way analysis of variance (ANOVA) (or Kruskal Wallis), t-test, or Fischer's exact test as appropriate. Odds ratio (OR) with a 95% confidence interval (CI) was used to predict factors relating to seizure outcome. Multiple logistic regression was used to determine factors which predict an Engel scale of 1 at one year follow up. The model included age at seizure onset, the number of medications used prior to surgery, the duration of epilepsy at surgery (these were done as both continuous and categorical variables), concordance of interictal or ictal EEG with the MRI, whether or not a PET or invasive EEG was performed, FCD confirmed on histology, epileptiform discharges on post-operative EEG and residual pathological tissue on the postoperative MRI scan.

Institutional approval for this study was waved by the ethics committee as it was a retrospective anonymous internal audit.

Results

Cohort Study

Patient records from 2012 to 2019 were scrutinised. 88 cases were identified from the magnetic resonance imaging (MRI) database. A further 367 cases were identified from a search of the electroencephalogram (EEG) database. Once duplicates and cases with a bony dysplasia were excluded, a total of 285 cases were collated. On further chart review 143 cases were excluded as their MRI scans were not reported as suggestive of focal cortical dysplasia (FCD) and the diagnosis had been erroneously entered in their EEG request or report, or they had an additional diagnosis such as polymicrogyria, tuberous sclerosis, or lissencephaly. Three patients with FCD had never had seizures and their FCD was found incidentally on an MRI scan performed for other reasons; these were excluded. The final sample analysed in this study consisted of

139 cases (figure 1). These were divided into two groups: group 1 consisted of 131 children (94.2%) with drug-resistant epilepsy. Over time seven of these children (5.3%) went on to become seizure free, following additional medical treatment (3 to 7 medications in total) and so a recommendation for conservative treatment was made. The majority of group 1 (116) had been referred for surgical assessment and subsequently discussed at the epilepsy surgery MDT meeting; group 2 consisted of 8 children (5.8%), who were seizure free on pharmacological treatment. There were slightly more males than females (56.5% vs 43.5% in the drug-resistant group; with 37.5% vs 62.5% for the drug responsive). The complete group characteristics are described in tables 1 and 2.

Drug-resistant versus drug-responsive epilepsy:

The average age of seizure onset in the drug-resistant group (group 1) was 2.8 years (range <1 month-14 years), with an average age of referral to GOSH of 5.94 years (1 month – 16 years). The average age of epilepsy surgery was 8 years of age (6 months - 18 years). The average time from seizure onset to referral was 3.2 years (<1 month – 14 years), whereas the average time from initial referral to surgery was 2.2 years (<1 month – 13 years). The average time from seizure onset to surgery was 5.5 years (2 months – 18 years).

The average age of seizure onset in the drug-responsive group (group 2) was 4.1 years (Under 1 month – 14). Average number of medications tried were 1.13 (vs 4.6 in the drug-resistant group ($p<0.001$)). 62.5% ($n=5$) became seizure free after commencing their first anti-seizure medication (ASM). A further 25% ($n=2$) became seizure free after addition or replacement with a second medication. One child had seizures which resolved without need for medication. In group 2 the average time from seizure onset to referral was less than in group 1 (2 years vs 3.2 years). This reached statistical significance with a $p=0.023$. Children with drug responsive epilepsy were referred at an earlier timepoint which may introduce a bias. However, we found

no association between time from seizure onset to surgery when analysing surgical outcomes (see table 3). Mean time of follow up for group 2 was 4.87 years.

Ictal EEG abnormalities, concordant with the MRI findings were significantly associated with drug-resistance (see Table 1). Ictal EEG: OR = 7.62 (95%CI 1.79-37.86, p=0.011). However, 50% (n=4) of those with pharmacoresponsive epilepsy (group 2) did not have an ictal EEG performed thus restricting our ability to infer conclusions from the ictal data. In addition, 3/131 (2.3%) patients of group 1 had normal interictal EEG, as opposed to 2/8 (25%) of group 2 (p=0.0263)

Epilepsy Surgery Outcomes:

Of the 131 patients with drug-resistant epilepsy, 116 were discussed at the epilepsy surgery MDT. Six children were not offered surgery. In five of these cases, it was concluded that surgery would result in too severe a neurological deficit, in one case the child became seizure free in the interim. Of those 110, 11 patients declined surgery and two patients were awaiting surgery at the time of data collection. In total 97 (74%) went on to have epilepsy surgery of whom 92 had one-year post-surgery follow up (table 2). 82/97 patients (84.5%) had resective surgery, while 15 (15.4%) had a disconnection surgery. Sixty-eight patients had a confirmed histology of FCD and 29 had non-FCD histology. Subtypes and percentages are detailed in table 2.

Fifty-five (59.8%) were seizure free (Engel class I) at one-year post surgery with 76 (82.6%) achieving at least a worthwhile improvement (Engel class III or better) (Table 2). Unadjusted factors significantly associated with an Engel class 1 at one year included seizure-onset after one year of age, no interictal epileptiform discharges on post-surgery EEG, location of FCD in the right hemisphere, and no residual FCD or unintended connection across surgical track on post-surgery MRI scan (table 3). However, only absence of interictal epileptiform discharges on post-surgery EEG, no residual FCD or connection on post-surgery MRI scan, and disease

affecting the right hemisphere remained significant in the multiple logistic regression model (table 4). Lobar location of the FCD was assessed against Engel also, no lobe was more associated with an Engel score at 1 year follow up, nor was multilobar disease. We assessed separately the complete removal of the "tail" of the FCD (radiological transmante sign). Out of the lesionectomy/lobectomy patients, 33 presented with a radiological "tail". Of these, 27 patients had a complete resection of the tail, according to postoperative MRI. 16/27 (59.9%) had an Engel 1 score, compared to 4/6 (66.6%) who did not have a complete resection. The difference was not statistically significant. When assessing age of onset and duration of epilepsy for Engel 1 versus 2-4 as a continuous variable, we found a significant effect for age at onset ($p=0.03$) with children under the age of one year having a lower rate of seizure freedom postoperatively (Figure 2a). The duration of epilepsy prior to an operation, however, did not seem to influence Engel score (Figure 2b).

Fifty percent of the non-FCD Histology group had an Engel score of 1. Even though this is a lower rate than the total, the difference between groups did not prove to be statistically significant.

Surgery safety outcome:

Of the 97 cases operated there was no peri-operative mortality. The adverse event rate was 6%. 4% were mild complications including transient mild paresis (1 patient), anaesthesia related drug reaction (1 patient), urinary catheter complication (1 patient) and superficial infection (1 patient) treated with antibiotics only, without surgical management. Two cases (2%) had a moderate complication of new onset motor deficit. However, at one year postoperative follow up, both had regained normal neurological function. There were no cases of permanent neurological deficit.

Survey

Sixteen responses were obtained in total, representing 30.7% (16/52) of the north London paediatric epilepsy network consultants. Within the practices of this subset of physicians, a total of 130 patients with epilepsy and presumed FCD were being managed. 112 of these had been referred to GOSH for management. That is, 86.2% of the patients with epilepsy and presumed FCD being treated within the network were referred to GOSH for further evaluation, regardless of whether seizures were controlled with medication.

Discussion

More than 94% (131/139) of the patients in our cohort of children presenting with epilepsy and presumed FCD on MRI had drug-resistant epilepsy. 110/139 patients (79%) were recommended for surgery. This demonstrates that most children presenting in this way will be surgical candidates and would likely benefit, as almost 60% of our surgical patients became seizure free post-operatively, in comparison to only 10.8% (8 drug-responsive patients and 7 patients with DRE who were seizure-free on more than 2 medications) of this patient-group, who were seizure free on medical treatment alone. Focal cortical dysplasia is associated with drug-resistant epilepsy.¹³⁻¹⁷ The high proportion of drug-resistance found in the current cohort has also been reported in the literature in this group of patients (FCD), although most of these series report the proportions in histologically defined cohorts, whereas this study reflects the clinical practice scenario considering a radiologically defined cohort as this is what is available at the time of initial referral to the neurologist/epileptologist considering pre-surgical evaluation.

There was a higher proportion of patients with concordant ictal EEG abnormalities and MRI lesions in the drug resistant cohort. Of note one third of the children with drug responsive epilepsy had bilateral interictal epileptiform discharges, raising the possibility that the FCD

may not be the only factor contributing to their epilepsy, or in fact, that the radiological diagnosis was incorrect, as these patients were not operated on and no histology was taken. These findings could imply contribution of additional aetiological factors, in these cases, that are more responsive to medical treatment. In our patient group, only 1.4% of the patients who failed the first medication, responded to a second. This is a much lower percentage than is found in the literature for epilepsy as a whole.¹⁸ This highlights that the delay to consider patients with an MRI diagnosis of FCD as suitable for surgical treatment until traditional criteria for drug-resistance are met, might be unnecessary.

A negative correlation has previously been reported between length of time from the first seizure to an operation, and both seizure outcome and cognitive ability.^{20,23,26-29} In a study performed by our department on low grade tumours, a sum of more than 20 seizures prior to surgical treatment was found to correlate with worse cognitive prognosis.²³ There is also evidence that intelligence quotient (IQ) declines over time with continuing seizures,³⁰ and IQ is more likely post-surgery to increase when medication is weaned as observed in the "time to stop" study.³³ Our cohort did not demonstrate an advantage to earlier surgery in terms of the seizure outcome. This study, however was neither designed, nor powered to do this. We were unable to obtain complete and accurate data on cognitive outcomes in our cohort. Nevertheless, there is evidence in the literature suggesting that early surgical treatment, resulting in seizure control, improves cognitive outcome.^{20,23,26-29} In a study by Pelliccia et al. two groups of patients with low grade tumours diagnosed at a young age were compared, one was operated in childhood, and the other operated in adulthood. One of the key points in that study was that shorter duration of epilepsy significantly correlated with better seizure outcome.³⁴ With the increased likelihood of a worthwhile reduction in seizures and reduced anti-epileptic medication burden offered by surgical treatment, one would expect improvement in quality of life measures. With these factors in mind and with the fact that in our cohort surgery was

effective with regard to seizure control, very safe with a low complication rate, and with no long-term negative sequelae, the case can be made for surgical treatment at an earlier stage for lesions that are EEG-MRI concordant in non-eloquent areas, before the traditional definition of drug-resistance is met. In cases where the epileptogenic lesion overlaps with eloquent cortex the risk : benefit balance of surgery will require more careful evaluation.

Engel class 1 outcome one year after surgery were 59.8%. This is in line with literature reports of 50-75% in most studies.¹⁹⁻²² We also accomplished an 82.6% rate of worthwhile seizure improvement (Engel class III or better-figure 3). Factors significantly associated with an Engel 1 outcome score were age above one year at diagnosis, no epileptiform activity on postoperative EEG, complete resection of the FCD on postoperative MRI scans and right hemisphere operations. Even though we have demonstrated that the completeness of the resection is important for seizure outcome, the complete removal of the "tail", or radiological transmantle sign, did not prove to be significant. The difference between hemispheres in seizure outcome could be due to the ability to perform a larger lesionectomy on the non-dominant side.

As stated before, the patients included were those with presumed FCD on preoperative MRI as well as epilepsy. On postoperative histology, however, only 69% of the samples had a confirmed diagnosis of FCD (table 2) and 13% of the cases had a nondiagnostic histology sample. There was no significant association between histology findings and surgical outcomes. There are several possible explanations for this finding. In deep or peri-eloquent resections, the use of ultrasonic aspiration whilst effective may limit histological specimen quality and much debate remains between histopathologists regarding the criteria for diagnosis or subtle malformations (eg FCD type 1 and mild malformations of cortical development).¹

Nevertheless, resection of lesions without histopathological diagnosis of FCD still resulted in 50% becoming seizure free.

There are several limitations to this study. One arises from the fact that GOSH is a specialist epilepsy centre with an epilepsy surgery program, and selection bias towards referral of patients with drug-resistant epilepsy cannot be excluded. In order to assess possible referral bias we performed a community-based survey. This indicated that the majority of children/young people with radiological FCD diagnosis resident in the geographical catchment area (86.2%), are referred to us whether or not they have shown response to medication. That being said, we only received response from 30% of the physicians requested to participate in the survey, thereby limiting our ability to draw meaningful conclusions. Furthermore, we cannot deduct that the referral pattern of our epilepsy network necessarily represents the pattern in other networks, both nationally and internationally. Another limitation lies in the retrospective nature of this study and the relatively short time of follow up of the postoperative patients.

Conclusion

In our cohort of patients with epilepsy and a radiologically presumed FCD, we show high rates of drug-resistance. Subsequent surgery results in favourable seizure outcomes with excellent safety profile, and given the fact that earlier surgery has the potential to improve seizure and cognitive outcome, this study provides further support to consider surgery in this cohort at an earlier stage than current standard practice. Further evaluation is necessary and a prospective study to assess the outcomes of earlier surgery for children with FCD associated epilepsy is needed.

Key points box:

-The vast majority of FCD-related epilepsy patients have drug-resistant epilepsy

-Most of these patients are surgical candidates and will have a significantly higher seizure-freedom, compared to medical treatment.

-This patient group should be considered for surgical treatment earlier than the current standard management.

Disclosure

J Helen Cross is supported by the National Institute of Health Research (NIHR) Biomedical Research Centre at Great Ormond Street Hospital. She has acted as an investigator for studies with GW Pharma, Zogenix, Vitaflo and Marinus. She has been a speaker and on advisory boards for GW Pharma, Zogenix, and Nutricia; all remuneration has been paid to her department. She holds an endowed chair at UCL Great Ormond Street Institute of Child Health; she holds grants from NIHR, EPSRC, GOSH Charity, ERUK, the Waterloo Foundation and the Great Ormond Street Hospital Biomedical Research Centre.

The remaining authors have no conflicts of interest.

Ethical publication statement

We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines

References

1. Blumcke I, Thom M, Aronica E, Armstrong DD, Vinters HV, Palmini A et al. The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. *Epilepsia* 2011;52:158–174.

2. Taylor DC, Falconer MA, Bruton CJ, Corsellis JA. Focal dysplasia of the cerebral cortex in epilepsy. *J Neurol Neurosurg Psychiatry* 1971;34:369–387.
3. Tassi L, Colombo N, Garbelli R, Francione S, Lo Russo G, Mai R et al. Focal cortical dysplasia: neuropathological subtypes, EEG, neuroimaging and surgical outcome. *Brain* 2002;125:1719–1732.
4. Tassi L, Garbelli R, Colombo N, Bramerio M, Lo Russo G, Mai R et al. Electroclinical, MRI and surgical outcomes in 100 epileptic patients with type II FCD. *Epileptic Disord* 2012;14:257–266.
5. Urbach H, Scheffler B, Heinrichsmeier T, Von Oertzen J, Kral T, Wellmer J et al. Focal cortical dysplasia of Taylor’s balloon cell type: a clinicopathological entity with characteristic neuroimaging and histopathological features, and favorable postsurgical outcome. *Epilepsia* 2002;43:33–40.
6. Fauser S, Huppertz HJ, Bast T, Strobl K, Pantazis G, Altenmueller DM et al. Clinical characteristics in focal cortical dysplasia: a retrospective evaluation in a series of 120 patients. *Brain* 2006;129:1907–1916.
7. Chassoux F, Landre E, Mellerio C, Turak B, Mann MW, Dumas-Duport C et al. Type II focal cortical dysplasia: electro-clinical phenotype and surgical outcome related to imaging. *Epilepsia* 2012;53:349–358.
8. Chassoux F, Rodrigo S, Semah F, Beuvon F, Landre E, Devaux B et al. FDG-PET improves surgical outcome in negative MRI Taylor-type focal cortical dysplasias. *Neurology* 2010;75:2168–2175.
9. Park SH, Pepkowitz SH, Kerfoot C, De Rosa MJ, Poukens V, Wienecke R et al. Tuberous sclerosis in a 20- week gestation fetus: immunohistochemical study. *Acta Neuropathol* 1997;94(2):180–186

10. Prabowo AS, Anink JJ, Lammens M, Nellist M, Van Den Ouweland AMW, Adle-Biassette H et al. Fetal brain lesions in tuberous sclerosis complex: TORC1 activation and inflammation. *Brain Pathol* 2013;23(1):45–59
11. Tsai V, Parker WE, Orlova KA, Baybis M, Chi AWS, Berg BD et al. Fetal brain mTOR signaling activation in tuberous sclerosis complex. *Cereb Cortex* 2014; 24(2):315–327
12. Rowland NC, Englot DJ, Cage TA, Sughrue ME, Barb NM, Chang EF. A meta-analysis of predictors of seizure freedom in the surgical management of focal cortical dysplasia. *J Neurosurg* 2012; 116:1035–1041
13. Guerrini R, Duchowny M, Jayakar P, Krsek P, Kahane P, Tassi L et al. Diagnostic methods and treatment options for focal cortical dysplasia. *Epilepsia*, 2015; 56(11):1669–1686.
14. Palmini A, Holthausen H. Focal malformations of cortical development: a most relevant etiology of epilepsy in children. *Handb Clin Neurol* 2013; 111:549–565.
15. Aronica E, Crino PB. Epilepsy related to developmental tumors and malformations of cortical development. *Neurotherapeutics* 2014; 11(2):251–268
16. Sisodiya SM. Malformations of cortical development: burdens and insights from important causes of human epilepsy. *Lancet Neurol* 2004;3(1):29–38
17. Semah F, Picot MC, Adam C, Broglin D, Arzimanoglou A, Bazin B et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? *Neurology* 1998 51:1256–1262
18. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Hauser A, Mathern G et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. *Epilepsia*, 2010; 51(6):1069–1077.

19. Chang E.F, Wang D.D, Barkovich A.J, Tihan T, Auguste K.I, Sullivan J.E et al. Predictors of seizure freedom after surgery for malformations of cortical development. *Ann. Neurol.* 2011 70, 151–162.
20. Radhakrishnan A, Menon R, Menon D, Singh A, Radhakrishnan N, Vilanilam G et al. Early resective surgery causes favorable seizure outcome in malformations of cortical development. *Epilepsy Research* 2016 124, 1–11
21. Choi SA, Kim KJ. The Surgical and Cognitive Outcomes of Focal Cortical Dysplasia. *J Korean Neurosurg Soc* 2019 62 (3): 321-327.
22. Hader WJ, Mackay M, Otsubo H, Chitoku S, Weiss S, Becker L et al. Cortical dysplastic lesions in children with intractable epilepsy: role of complete resection. *J Neurosurg (Pediatrics 2)* 2004 100:110–117
23. Faramand AM, Barnes N, Harrison S, Gunny R, Jacques T, Tahir MZ et al. Seizure and cognitive outcomes after resection of glioneuronal tumors in children. *Epilepsia.* 2018; 59:170–178.
24. Xu DS, Awad AW, Mehalechko C, Wilson JR, Ashby LS, Coons SW et al. An extent of resection threshold for seizure freedom in patients with low-grade gliomas. *J Neurosurg* 2018; 128:1084–1090.
25. Pallud J, McKhann GM. Diffuse Low-Grade Glioma-Related Epilepsy. *Neurosurg Clin N Am* 2019 30 43–54.
26. Luyken C, Blümcke I, Fimmers R, Urbach H, Elger C.E, Wiestler O.D et al. The spectrum of long-term epilepsy-associated tumors: long-term seizure and tumor outcome and neurosurgical aspects. *Epilepsia* 2003 44, 822–830.
27. Otsuki T, Honda R, Takahashi A, Kaido T, Kaneko Y, Nakai T et al. Surgical management of cortical dysplasia in infancy and early childhood. *Brain & Development* 2013. 35 802–809

28. O'Reilly H, Eltze C, Bennett K, Verhaert K, Webb R, Merrett A et al. Cognitive outcomes following epilepsy in infancy: A longitudinal community-based study. *Epilepsia*. 2018; 59:2240–2248.
29. Soleman J, Stein M, Knorr C, Datta AN, Constantini S, Fried I et al. Improved quality of life and cognition after early vagal nerve stimulator implantation in children. *Epilepsy & Behavior* 88 (2018) 139–145.
30. Braun KPJ. Influence of epilepsy surgery on developmental outcomes in children. *Eur J Paediatr Neurol*. 2020 Jan;24:40-42.
31. Engel J. Update on Surgical Treatment of the Epilepsies. Summary of the Second International Palm Desert Conference on the Surgical Treatment of the Epilepsies. *Neurology* 1993; 43(8):1612-7
32. Fauser S, Bast T, Altenmüller DM, Schulte-Moünting J, Strobl K, Steinhoff BJ et al. Factors influencing surgical outcome in patients with focal cortical dysplasia. *J Neurol Neurosurg Psychiatry* 2008; 79:103–105
33. Boshuisen K, Van Schooneveld MMJ, Uiterwaal CSPM, Cross H, Harrison S, Polster T et al. Intelligence Quotient Improves after Antiepileptic Drug Withdrawal following Pediatric Epilepsy Surgery. *Ann Neurol* 2015;78:104–114
34. Pelliccia V, Deleo F, Gozzo F, Sartori I, Mai R, Cossu M et al. Early and late epilepsy surgery in focal epilepsies associated with long-term epilepsy-associated tumors. *J Neurosurg* 2017;127:1147–1152.

Figure legend:

Figure 1: Flowchart describing patient identification, eligibility assessment and included cohort.

Figure 2: Kernel density estimate of age at seizure onset (A) and duration of epilepsy (B) prior to surgery, stratified by Engel outcome.

Figure 3: Engel classification at 1-year post surgery

Tables:

Table 1. Comparison of drug resistant and drug responsive groups.

	<i>Drug resistant Epilepsy (n=131)94.2%</i>	<i>Drug responsive Epilepsy (n=8) 5.8%</i>	<i>Odds Ratio (95% CI)</i>	<i>p value</i>
	n (%)	n (%)		
<i>Males</i>	74 (56.5%)	3 (37.5%)		
<i>Females</i>	57 (43.5%)	5 (62.5%)		
<i>Average age of seizure onset (years) (range)</i>	2.8 (under 1 month – 14)	4.1 (Under 1 month – 14)		0.120
<i>Average age at referral (years) (range)</i>	5.94 (1 month -16)	6.1 (1 – 15.3)		0.983
<i>Average time from seizure onset to referral (years) (range)</i>	3.2 (<1 – 12.34)	2 (0.4 – 9.75)		0.023
<i>Average time from seizure onset to epilepsy surgery (years) (range)</i>	5.5 (2 months – 18 years)			
<i>Average time from referral to epilepsy surgery (years) (range)</i>	2.2 (<1 month – 13)			
<i>Average Age at Epilepsy Surgery (years) (range)</i>	8 (6 months – 18 years)			
<i>Average number of medications used (range)</i>	4.6 (1-10)	1.13 (0-2)		<0.0001
<i>Laterality of FCD</i>	Right 71 (54.2%) Left 60 (45.8%)	Right 5 (62.5%) Left 3 (37.5%)	1.41 (0.35:5.48)	0.7285
<i>Bilateral interictal EEG abnormalities</i>	16 (12.2%)	5 (33.33%)	0.08 (0.02:0.88)	0.0021
<i>Ictal EEG not captured</i>	9 (6.9%)	4 (50%)		
<i>Interictal EEG normal</i>	3 (2.3%)	2 (25%)	0.07 (0.01:0.47)	0.0263
<i>MRI and Interictal EEG Concordant</i>	97 (74%)	4 (50%)	2.85 (0.79:10.15)	0.214
<i>MRI and Ictal EEG Concordant</i>	94 (71.8%)	2 (25%)	7.62 (1.79:37.86)	0.011
<i>Ictal and Interictal EEG Concordant</i>	101 (77%)	1 (0.125%)	23.57 (3.86:267.4)	0.0004
<i>Ictal, Interictal and MRI Concordant</i>	88 (67.2%)	1 (0.125%)	14.33 (2.402:162.9)	0.0033

Abbreviations: Electroencephalogram (EEG), Magnetic Resonance Imaging (MRI), Focal Cortical Dysplasia (FCD), Confidence Interval (CI)

Table 2. Pharmacoresistant and epilepsy surgery patients.

<i>Drug resistant Epilepsy</i>	<i>Number (percentage, of total unless otherwise specified)</i>
<i>Total</i>	131
<i>Underwent epilepsy surgery</i>	97 (74%)
<i>Resective surgery</i>	82 (62.6%)
<i>Disconnection</i>	15 (11.5%)
<i>Surgery recommended but parents declined</i>	11 (8.4%)
<i>Evaluated but not felt to be a surgical candidate</i>	6 (4.6%)
<i>Awaiting discussion or surgery</i>	4 (3.1%)
<i>Not referred for surgical assessment</i>	6 (4.6%)
<i>PET scan performed</i>	29 (22.1%)
<i>Invasive monitoring performed</i>	30 (22.9%)
<i>>1 year post surgery follow up</i>	92 (70.2%)
<i>Engel Scale 1 at 1 year follow up</i>	55 – (59.8% of those > 1 year post surgery)
<i>Engel 1-3 at 1 year follow up</i>	76 – (82.6% of those > 1 year post surgery)
<i>Engel Scale 4 at 1 year follow up</i>	16 – (17.4% of those > 1 year post surgery)
<i>Required further epilepsy surgery</i>	13 – (14.1% of those > 1-year post surgery). 1 underwent vagal nerve stimulator implantation
<i>Histology confirmed FCD</i>	68 (70% of surgical cohort); Resection 71.4%, Disconnection 60%, p=0.3762
<i>Histology nondiagnostic</i>	13 (13.4% of surgical cohort)
<i>Engel Scale 1 in those with confirmed FCD</i>	41 (64% of FCD 1 year post surgery)
<i>Engel Scale 1 in those with non-FCD histology</i>	14 (50% of those 1 year post surgery)
<i>FCD Subtypes (% total FCD)</i>	FCD Type 2a - 12 (17.6%) FCD Type 2b - 47 (69.2%) FCD – subtype unknown - 9 (13.2%)
<i>Other Histology (n=29)</i>	Non-diagnostic - 19 Gliosis – 3 Polymicrogyria – 2 Normal – 1 Glioneuronal tumour – 1 Low grade ganglioglioma (NOS) – 1 Hippocampal sclerosis (no FCD) – 1 Pleomorphic xanthoastrocytoma (PXA) – 1

Abbreviations: Focal cortical dysplasia (FCD), Positron emission tomography (PET), Multidisciplinary Team (MDT)

Table 3. Factors affecting surgical outcome. Base on the 92 patients > 1-year post surgery.

<i>Unadjusted Values</i>	<i>Odds Ratio of Engel 1 at 1 year</i>	<i>95% Confidence Interval</i>	<i>p value</i>
<i>Age > 1 year at seizure onset</i>	2.56	1.15 to 6.04	0.0355
<i>Less than 2 years from presentation to surgery</i>	1.62	0.59 to 4.11	0.457
<i>Interictal and ictal EEG concordant</i>	1.07	0.35 to 3.51	>0.9999
<i>Interictal EEG and MRI correlate</i>	2.176	0.8 to 6.49	0.182
<i>Ictal EEG and MRI correlate</i>	1.64	0.59 to 4.57	0.424
<i>Ictal EEG, Interictal EEG and MRI all correlate</i>	1.69	0.62 to 4.66	0.325
<i>Right hemispheric FCD</i>	2.66	1.15 to 5.92	0.033
<i>PET scan performed</i>	1.6	0.59 to 4.11	0.457
<i>Invasive EEG performed</i>	0.46	0.18 to 1.11	0.105
<i>Resective Surgery v Disconnection</i>	0.99	0.31 to 3.12	>0.9999
<i>Histology confirmed FCD</i>	1.78	0.76 to 4.2	0.251
<i>No residual Disease or Connection on Post-op MRI</i>	3.63	1.49 to 8.69	0.0048
<i>No epileptiform discharges on post-op EEG</i>	4.57	1.75 to 11.12	0.0017

Abbreviations: Positron emissions tomography (PET), electroencephalogram (EEG), magnetic resonance imaging (MRI), focal cortical dysplasia (FCD), postoperative (post-op).

Table 4. Multiple Logistic regression model of factors affecting likelihood of Engel 1 outcome at 1-year post surgery.

Adjusted values	Odds ratio of Engel 1 at 1 year	95% confidence interval	p value
Age at seizure onset	1.23	1.004 to 1.57	0.059
Number of AEDs	0.93	0.72 to 1.22	0.588
Number of years from seizure onset to surgery	0.96	0.82 to 1.11	0.558
Interictal EEG, ictal EEG, and MRI concordant	2.71	0.70 to 11.78	0.158
RIGHT HEMISPHERIC FCD	3.63	1.19 to 12.37	0.029
FCD confirmed on histology	2.23	0.66 to 8.11	0.204
Epileptiform discharges on post-surgery EEG	0.27	0.1 to 0.84	0.023
Residual disease on post-surgery MRI	0.26	0.08 to 0.73	0.013

Abbreviations: Antiepileptic drugs (AEDs), electroencephalogram (EEG), magnetic resonance imaging (MRI), positron emission tomography (PET), focal cortical dysplasia (FCD).

Supporting information

Appendix S1:

https://www.surveymonkey.com/r/Preview/?sm=R7MXq52spHw6I2BYX7zvvI4QPjFXbYHgqJT7N8f3fAjr2_2F_2FnI0kRnSIFnEYs2oeQ